Regeneron Pharmaceuticals Inc. buy Jefferies Financial Group Inc.
Summary
This prediction is currently active. With a performance of 33.44% the BUY prediction by Jefferies_Financial_ is a big success. This prediction currently runs until 28.11.24. The prediction end date can be changed by Jefferies_Financial_ at any time. Jefferies_Financial_ has 50% into this predictionRegeneron Pharmaceuticals, Inc. is a biotechnology company that is engaged in the discovery, development, and commercialization of medicines for the treatment of serious medical conditions. The company's products include EYLEA, a treatment for wet age-related macular degeneration and diabetic macular edema; Dupixent, a treatment for atopic dermatitis and asthma; and Libtayo, a treatment for certain types of cancer. Regeneron also has a strong focus on research and development, with a pipeline of potential new treatments for a variety of diseases. The company is headquartered in Tarrytown, New York and trades on the NASDAQ stock exchange under the symbol REGN.
Performance without dividends (%)
Name | 1w | 1m |
---|---|---|
Regeneron Pharmaceuticals Inc. | -3.156% | -3.156% |
iShares Core DAX® | -0.116% | 1.953% |
iShares Nasdaq 100 | -2.733% | -1.273% |
iShares Nikkei 225® | -1.721% | 3.263% |
iShares S&P 500 | -1.527% | 0.194% |
Comments by Jefferies_Financial_ for this prediction
In the thread Regeneron Pharmaceuticals Inc. diskutieren